Clinical Trial Update: Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ra-223 dichloride in combination with hormonal therapy and denosumab in hormone-positive bone-dominant metastatic breast cancer has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Denosumab (denosumab)
• Hormonal Therapy
• Ra-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-10-07